OBJECTIVE: To determine the relationship between incident depression symptoms and suboptimal adherence to HIV highly active antiretroviral therapy (HAART). METHODS: Participants in a cohort study of persons with HIV on HAART with at least 4 consecutive semiannual study visits were included (n = 225). Incident depression was defined as having 2 visits with a negative depression screening test followed by 2 visits with a positive test. Comparison group participants had 4 consecutive visits with a negative depression screening test. Suboptimal adherence was defined as missing >5% of HAART doses in the past 7 days. We compared suboptimal adherence rates in those with and without incident depression symptoms and estimated the relative risk and 95% confidence intervals of suboptimal adherence at visit 4 in those adherent at baseline (n = 177), controlling for sociodemographic, behavioral, and clinical variables. RESULTS: Twenty-two percent developed depression symptoms. Those developing depression symptoms had higher rates of suboptimal adherence at follow-up (45.1% vs. 25.9%, P < 0.01). Among those with optimal baseline adherence, those with incident depression were nearly 2 times more likely to develop suboptimal adherence (Adjusted relative risk =1.8, 95% confidence interval =1.1 to 3.0) at follow-up. CONCLUSION: Incident depression symptoms were associated with subsequent suboptimal HAART adherence. Ongoing aggressive screening for, and treatment of, depression may improve HAART outcomes.
OBJECTIVE: To determine the relationship between incident depression symptoms and suboptimal adherence to HIV highly active antiretroviral therapy (HAART). METHODS:Participants in a cohort study of persons with HIV on HAART with at least 4 consecutive semiannual study visits were included (n = 225). Incident depression was defined as having 2 visits with a negative depression screening test followed by 2 visits with a positive test. Comparison group participants had 4 consecutive visits with a negative depression screening test. Suboptimal adherence was defined as missing >5% of HAART doses in the past 7 days. We compared suboptimal adherence rates in those with and without incident depression symptoms and estimated the relative risk and 95% confidence intervals of suboptimal adherence at visit 4 in those adherent at baseline (n = 177), controlling for sociodemographic, behavioral, and clinical variables. RESULTS: Twenty-two percent developed depression symptoms. Those developing depression symptoms had higher rates of suboptimal adherence at follow-up (45.1% vs. 25.9%, P < 0.01). Among those with optimal baseline adherence, those with incident depression were nearly 2 times more likely to develop suboptimal adherence (Adjusted relative risk =1.8, 95% confidence interval =1.1 to 3.0) at follow-up. CONCLUSION: Incident depression symptoms were associated with subsequent suboptimal HAART adherence. Ongoing aggressive screening for, and treatment of, depression may improve HAART outcomes.
Authors: J H Arnsten; P A Demas; H Farzadegan; R W Grant; M N Gourevitch; C J Chang; D Buono; H Eckholdt; A A Howard; E E Schoenbaum Journal: Clin Infect Dis Date: 2001-09-05 Impact factor: 9.079
Authors: Jasjit S Ahluwalia; Kimber Richter; Matthew S Mayo; Harsohena K Ahluwalia; Won S Choi; Kristin H Schmelzle; Ken Resnicow Journal: Ann Epidemiol Date: 2002-04 Impact factor: 3.797
Authors: H Liu; C E Golin; L G Miller; R D Hays; C K Beck; S Sanandaji; J Christian; T Maldonado; D Duran; A H Kaplan; N S Wenger Journal: Ann Intern Med Date: 2001-05-15 Impact factor: 25.391
Authors: D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh Journal: Ann Intern Med Date: 2000-07-04 Impact factor: 25.391
Authors: E G Bing; M A Burnam; D Longshore; J A Fleishman; C D Sherbourne; A S London; B J Turner; F Eggan; R Beckman; B Vitiello; S C Morton; M Orlando; S A Bozzette; L Ortiz-Barron; M Shapiro Journal: Arch Gen Psychiatry Date: 2001-08
Authors: V E Stone; J W Hogan; P Schuman; A M Rompalo; A A Howard; C Korkontzelou; D K Smith Journal: J Acquir Immune Defic Syndr Date: 2001-10-01 Impact factor: 3.731
Authors: Jane M Simoni; Steven A Safren; Lisa E Manhart; Karen Lyda; Cynthia I Grossman; Deepa Rao; Matthew J Mimiaga; Frank Y Wong; Sheryl L Catz; Michael B Blank; Ralph DiClemente; Ira B Wilson Journal: AIDS Behav Date: 2011-02
Authors: Alexander C Tsai; Dan H Karasic; Gwendolyn P Hammer; Edwin D Charlebois; Kathy Ragland; Andrew R Moss; James L Sorensen; James W Dilley; David R Bangsberg Journal: Am J Public Health Date: 2012-06-21 Impact factor: 9.308
Authors: Rachel Rinehart; Deep Rao; Rivet K Amico; Eduardo Ruiz; Peter Brandes; Cecilia Correa; Siavash Pasalar; Javier R Lama; Ann Duerr; Yamile Molina Journal: AIDS Behav Date: 2019-03
Authors: Bryna J Harrington; Brian W Pence; Mathias John; Caroline G Melhado; Jacob Phulusa; Bryan Mthiko; Bradley N Gaynes; Joanna Maselko; William C Miller; Mina C Hosseinipour Journal: J Ment Health Date: 2018-09-29
Authors: Heather J Ribaudo; Kimberly Y Smith; Gregory K Robbins; Charles Flexner; Richard Haubrich; Yun Chen; Margaret A Fischl; Bruce R Schackman; Sharon A Riddler; Roy M Gulick Journal: Clin Infect Dis Date: 2013-09-17 Impact factor: 9.079
Authors: L S Eller; M Rivero-Mendez; J Voss; W-T Chen; P Chaiphibalsarisdi; S Iipinge; M O Johnson; C J Portillo; I B Corless; K Sullivan; L Tyer-Viola; J Kemppainen; C Dawson Rose; E Sefcik; K Nokes; J C Phillips; K Kirksey; P K Nicholas; D Wantland; W L Holzemer; A R Webel; J M Brion Journal: AIDS Care Date: 2013-10-04